Integra Therapeutics
Integra Therapeutics develops a gene writing platform called FiCAT that combines CRISPR-Cas precision with engineered piggybac transposase protein efficiency. The technology is designed to deliver both small and large genetic payloads to treat oncological and autoimmune diseases with high unmet medical needs. The platform aims to improve the scope and stability of advanced therapies by enabling the insertion of multiple therapeutic genes in a single intervention.
Visit websiteBarcelona, Spain
Biotechnology
Gene Therapy
Healthtech
Funding summary
- Total raised
- €27.2M
- Funding rounds
- 4
Investors in Integra Therapeutics
Investors on record for Integra Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Integra Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors